Albany, US – DelveInsight has launched a new report on Uveitis Market Insights, Epidemiology and Market Forecast-2030
DelveInsight’s “Uveitis – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Uveitis , historical and forecasted epidemiology as well as the Uveitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Report:
- The therapeutic market of Uveitis in the seven major markets was USD 1027.0 million in 2017.
- The total prevalent cases of Uveitis in the US were observed to be 357,791 in 2017.
- In 2017, it was found that there were 26,550 diagnosed cases of infectious uveitis in the
United States.
- In 2017, it was found that there were 277,573 diagnosed cases of non-infectious uveitis in the United States.
Key benefits of the Report
1. Uveitis market report covers a descriptive overview and comprehensive insight of the Uveitis epidemiology and Uveitis market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Uveitis market report provides insights on the current and emerging therapies.
3. Uveitis market report offers a global historical and forecasted market covering drug outreach in 7 MM.
4. Uveitis market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Uveitis market.
Request for Sample Pages: https://www.delveinsight.com/sample-request/uveitis-market
“According to DelveInsight, the majority of cases of Uveitis are female as compared to male. There were total 154,190 female and 149,932 male cases of Uveitis in 2017 in the United States.”
Prevent Blindness Organization defines Uveitis as, a term for inflammation of the eye. It is an inflammation of the uvea, the pigmented layer that lies between the inner retina and the outer fibrous layer composed of the sclera and cornea. It is caused by inflammatory responses inside the eye that can be caused due to tissue damage, germs, or toxins which lead swelling, redness, heat, and destroys tissues as certain white blood cells rush to the affected part.
Uveitis is classified anatomically as anterior, intermediate, posterior, or diffuse. Anterior uveitis typically refers to inflammation of the iris and anterior chamber; intermediate uveitis refers to inflammation of the ciliary body and vitreous humor (the jellylike filling in the anterior portion of the eye); and posterior uveitis refers to inflammation of the retina, choroid, or the optic disk (where the optic nerve enters the retina). Diffuse uveitis (Panuveitis) implies inflammation of the entire uveals tract.
Symptoms of acute forms of uveitis include ocular pain, photophobia, lacrimation, and redness. Uveitis is most often idiopathic but has been associated with traumatic, inflammatory, and infectious processes.
Some of the key companies working on Uveitis are:
- Santen
- EyeGate Pharmaceuticals
- Sanofi
- Oculis Pharma
- Novartis
And Many Others.
The launch of the emerging therapies is expected to significantly impact the Uveitis treatment scenario in the upcoming years:-
Drugs Covered:
- Sirolimus
- EGP-437
- Sarilumab
- LME636 (OCS-02)
- LFG316
And Many Others.
Request a Free Sample Report @ https://www.delveinsight.com/sample-request/uveitis-market
Table of Contents:
1. Key Insight
2. Uveitis Market Overview at a Glance
2.1. Market Share (%) Distribution of Uveitis in 2017
2.2. Market Share (%) Distribution of Uveitis in 2030
3. Disease Background and Overview: Uveitis
3.1. Introduction
3.2. Classification of Uveitis
3.3. International Uveitis Study Group (IUSG) Clinical Classification of Uveitis
3.4. The Standardization of Uveitis Nomenclature (SUN) Working Group
3.5. Symptoms of Uveitis
3.6. Pathophysiology
3.7. Etiology of Uveitis
3.8. Diagnosis of Uveitis
3.8.1. American Academy of Family Physicians
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Prevalent Population of Uveitis in the 7MM
4.3. Diagnosed Prevalent Population of Uveitis in the 7MM
4.4. Type Specific Diagnosed Prevalent Population of Uveitis in the 7MM
5. United States-Epidemiology of Uveitis
5.1. Assumptions and Rationale
5.2. Total Prevalent Population of Uveitis in the United States
5.3. Diagnosed Prevalent Population of Uveitis in the United States
5.4. Gender-Specific Diagnosed Prevalent Population of Uveitis in United States
5.5. Age-Specific Diagnosed Prevalent Population of Uveitis in United States
5.6. Type Specific Diagnosed Prevalent Population of Uveitis in United States
5.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location
5.7.1. Diagnosed prevalent cases of Anterior noninfectious Uveitis (aNIU) in the United States
5.7.2. Diagnosed prevalent cases of Nonanterior NIU (Posterior Segment) or NIPU in the US
5.8. Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in the US
6. EU-5 Epidemiology of Uveitis
6.1. Germany
6.1.1. Assumptions and Rationale
6.1.2. Prevalent Population of Uveitis in Germany
6.1.3. Diagnosed Prevalent Population of Uveitis in Germany
6.1.4. Gender Specific Diagnosed Prevalence of Uveitis in Germany
6.1.5. Age Group Specific Diagnosed Prevalence of Uveitis in Germany
6.1.6. Type Specific Diagnosed Prevalence of Uveitis in Germany
6.1.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location
6.1.8. Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Germany
6.2. France
6.2.1. Assumptions and Rationale
6.2.2. Prevalent Population of Uveitis in France
6.2.3. Diagnosed Prevalent Population of Uveitis in France
6.2.4. Gender Specific Diagnosed Prevalence of Uveitis in France
6.2.5. Age Specific Diagnosed Prevalence of Uveitis in France
6.2.6. Type Specific Diagnosed Prevalence of Uveitis in France
6.2.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location
6.2.8. Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in France
6.3. Italy
6.3.1. Assumptions and Rationale
6.3.2. Prevalent Population of Uveitis in the Italy
6.3.3. Diagnosed Prevalent Population of Uveitis in Italy
6.3.4. Gender Specific Diagnosed Prevalence of Uveitis in Italy
6.3.5. Age Specific Diagnosed Prevalence of Uveitis in Italy
6.3.6. Type Specific Diagnosed Prevalence of Uveitis in Italy
6.3.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location
6.3.8. Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Italy
6.4. Spain
6.4.1. Assumptions and Rationale
6.4.2. Prevalent Population of Uveitis in the Spain
6.4.3. Diagnosed Prevalent Population of Uveitis in Spain
6.4.4. Gender Specific Diagnosed Prevalence population of Uveitis in Spain
6.4.5. Age Specific Diagnosed Prevalence of Uveitis in Spain
6.4.6. Type Specific Diagnosed Prevalence of Uveitis in Spain
6.4.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Spain
6.4.8. Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Spain
6.5. United Kingdom
6.5.1. Assumptions and Rationale
6.5.2. Prevalent Population of Uveitis in the UK
6.5.3. Diagnosed Prevalent Population of Uveitis in United Kingdom
6.5.4. Gender Specific Diagnosed Prevalence of Uveitis in UK
6.5.5. Age Specific Diagnosed Prevalence of Uveitis in UK
6.5.6. Type Specific Diagnosed Prevalence of Uveitis in UK
6.5.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in the UK
6.5.8. Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in the UK
7. Japan
7.1. Assumptions and Rationale
7.2. Prevalent Population of Uveitis in the Japan
7.3. Diagnosed Prevalent Population of Uveitis in the Japan
7.4. Gender Specific Prevalence of Uveitis in Japan
7.5. Age Specific Prevalence of Uveitis in Japan
7.6. Type Specific Prevalence of Uveitis in Japan
7.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Japan
7.8. Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Japan
8. Treatment of Uveitiss
8.1. Treatment Algorithm
8.2. First Line of Therapy: Corticosteroids
8.3. Second Line of Therapy: Immunosuppressants
8.4. Third Line of Therapy: Biologics
8.5. Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis:
Fundamentals of Care for Uveitis (FOCUS) Initiative
9. Unmet Needs
10. Marketed Drugs
10.1. Key Cross Competition
10.2. Durezol: Sirion Therapeutics
10.2.1. Product Description
10.2.2. Regulatory Milestones
10.2.3. Advantages & Disadvantages
10.2.4. Safety and Efficacy
10.2.5. Product Profile
10.3. Triesence: Novartis
10.3.1. Drug Description
10.3.2. Regulatory Milestones
10.3.3. Advantages & Disadvantages
10.3.4. Safety and Efficacy
10.3.5. Product Profile
10.4. Retisert: Valeant Pharmaceuticals International Inc
10.4.1. Drug Description
10.4.2. Regulatory Milestones
10.4.3. Advantages & Disadvantages
10.4.4. Safety
10.4.5. Efficacy
10.4.6. Product Profile
10.5. Ozurdex: Allergan plc
10.5.1. Drug Description
10.5.2. Regulatory Milestones
10.5.3. Advantages & Disadvantages
10.5.4. Efficacy
10.5.5. Safety
10.5.6. Product Profile
10.6. Humira: AbbVie Inc.
10.6.1. Drug Description
10.6.2. Regulatory Milestones
10.6.3. Advantages & Disadvantages
10.6.4. Safety and Efficay
10.6.5. Product Profile
10.7. Yutiq: Eyepoint Pharmaceuticals
10.7.1. Product Description
10.7.2. Clinical Development
10.7.3. Advantages & Disadvantages
10.7.4. Safety and Efficacy
10.7.5. Product Profile
10.8. Tobradex: Alcon Laboratories
10.8.1. Product Description
10.8.2. Other Developmental Activities
10.8.3. Product Profile
10.9. Acthar: Mallinckrodt
10.9.1. Product Description
10.9.2. Other Developmental Activities
10.9.3. Advantages and Disadvantages
10.9.4. Safety and Efficacy
10.9.5. Product Profile
10.10. Iluvien: Alimera Sciences
10.10.1. Product Description
10.10.2. Other Developmental Activities
10.10.3. Clinical Development
10.10.4. Clinical Trials Information
10.10.5. Safety and Efficacy
10.10.6. Product Profile
11. Emerging Drugs Analysis
11.1. Key Cross Competition
11.2. ADX-102: Aldeyra Therapeutics Inc.
11.2.1. Product Description
11.2.2. Advantages & Disadvantages
11.2.3. Clinical Development
11.2.4. Safety and Efficacy
11.2.5. Product Profile
11.3. Sirolimus: Santen
11.3.1. Product Description
11.3.2. Regulatory Milestones
11.3.3. Advantages & Disadvantages
11.3.4. Clinical Development
11.3.5. Safety and Efficacy
11.3.6. Product Profile
11.4. EGP-437: EyeGate Pharmaceuticals
11.4.1. Product Description
11.4.2. Regulatory Milestones
11.4.3. Advantages & Disadvantages
11.4.4. Clinical Development
11.4.5. Safety and Efficacy
11.4.6. Product Profile
11.5. Suprachoroidal CLS-TA: Clearside Biomedical, Inc.
11.5.1. Product Description
11.5.2. Clinical Development
11.5.3. Safety and Efficacy
11.5.4. Product Profile
11.6. Sarilumab: Sanofi Aventis
11.6.1. Product Description
11.6.2. Product Development Activities
11.6.3. Advantages and Disadvantages
11.6.4. Clinical Development
11.6.5. Safety and Efficacy
11.6.6. Product Profile
11.7. LME636 (OCS-02): Oculis Pharma
11.7.1. Product Description
11.7.2. Other development activities
11.7.3. Clinical Development
11.7.4. Safety and Efficacy
11.7.5. Product Profile
11.8. LFG316: Novartis
11.8.1. Product Description
11.8.2. Other development activities
11.8.3. Clinical Development
11.8.4. Safety and Efficacy
11.8.5. Product Profile
11.9. Abatacept (Orenica): Bristol-Myers Squibb Company
11.9.1. Product Description
11.9.2. Clinical Development
11.9.3. Safety and Efficacy
11.9.4. Product Profile
11.10. EYS606: Eyevensys
11.10.1. Product Description
11.10.2. Other development activities
11.10.3. Clinical Development
11.10.4. Safety and Efficacy
11.10.5. Product Profile
12. Uveitis: 7 Major Market Analysis
12.1. Key Findings
12.2. Market Size of Uveitis in the 7MM
12.3. Market Size of Uveitis by Therapies in the 7MM
13. United States: Market Outlook
13.1. Total Market size of Uveitis
13.2. Uveitis Market Size by Therapies
14. EU5: Market Outlook
14.1. Germany Market Size
14.1.1. Total Market size of Uveitis
14.1.2. Uveitis Market Size by Therapies
14.2. France Market Size
14.2.1. Total Market size of Uveitis
14.2.2. Uveitis Market Size by Therapies
14.3. Italy Market Size
14.3.1. Total Market size of Uveitis
14.3.2. Uveitis Market Size by Therapies
14.4. Spain Market Size
14.4.1. Total Market size of Uveitis
14.4.2. Uveitis Market Size by Therapies
14.5. United Kingdom Market Size
14.5.1. Total Market size of Uveitis
14.5.2. Uveitis Market Size by Therapies
15. Japan: Market Outlook
15.1. Japan: Market Size
15.1.1. Total Market size of Uveitis
15.1.2. Uveitis Market Size by Therapies
16. Market Drivers
17. Market Barriers
18. Appendix
19. Report Methodology
19.1. Sources Used
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight
Related Reports:
Uveitis – Pipeline Insights, 2020
The Uveitis report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Uveitis across the complete product development cycle, including all clinical and nonclinical stages.
Uveitis – Epidemiology Forecast to 2030
The Uveitis epidemiology covered in the report provides historical as well as forecasted Uveitis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NEVADA 89107
Country: United States
Website: https://www.delveinsight.com/